-
Product Insights
NewLikelihood of Approval Analysis for Ocular Melanoma
Overview How likely is it that the drugs in Ocular Melanoma will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocular Melanoma Overview Ocular melanoma is an extremely rare form of cancer...
-
Product Insights
NewLikelihood of Approval Analysis for Ocular Hypertension
Overview How likely is it that the drugs in Ocular Hypertension will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocular Hypertension Overview Ocular hypertension occurs when the pressure inside the eye...
-
Product Insights
NewLikelihood of Approval Analysis for Ocular Inflammation
Overview How likely is it that the drugs in Ocular Inflammation will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocular Inflammation Overview Ocular inflammation is an eye inflammation that include choroiditis,...
-
Product Insights
NewLikelihood of Approval Analysis for Ocular Pain (Eye Pain)
Overview How likely is it that the drugs in Ocular Pain (Eye Pain) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocular Pain (Eye Pain) Overview Ocular pain, commonly known as...
-
Product Insights
NewNet Present Value Model: Ocular Therapeutix Inc’s Axitinib
Empower your strategies with our Net Present Value Model: Ocular Therapeutix Inc's Axitinib report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sepetaprost in Ocular Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sepetaprost in Ocular Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sepetaprost in Ocular Hypertension Drug Details: Sepetaprost (DE-126) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Ocular Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Ocular Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Ocular Melanoma Drug Details: Spartalizumab (PDR-001) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Docetaxel in Ocular Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel in Ocular Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Docetaxel in Ocular Melanoma Drug Details: Docetaxel (nano-formulation) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CX-2029 in Ocular Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CX-2029 in Ocular Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CX-2029 in Ocular Melanoma Drug Details: CX-2029 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGENT-797 in Ocular Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGENT-797 in Ocular Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGENT-797 in Ocular Melanoma Drug Details: AGENT-797 is under development for...